ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)-Reference-Cited by-同舟云学术

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)

Published:2018-06 Issue: Volume:24 Page:S53-S70
ISSN:1198-743X
Container-title:Clinical Microbiology and Infection
language:en
Short-container-title:Clinical Microbiology and Infection

Author:

Reinwald M.,Silva J.T.,Mueller N.J.,Fortún J.,Garzoni C.,de Fijter J.W.,Fernández-Ruiz M.,Grossi P.,Aguado J.M.

Funder

Spanish Network for Research in Infectious Diseases

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference236 articles.

1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction);Fernández-Ruiz;Clin Microbiol Infect,2018

2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies: an infectious diseases perspective (cell surface receptors and associated signaling pathways);Aguilar-Company;Clin Microbiol Infect,2018

3. Chronic myeloid leukemia: overview of new agents and comparative analysis;Jain;Curr Treat Options Oncol,2013

4. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib;Hantschel;Leuk Lymphoma,2008

5. Specific targeted therapy of chronic myelogenous leukemia with imatinib;Deininger;Pharmacol Rev,2003

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CMV reactivation during pretransplantation evaluation: a novel risk factor for posttransplantation CMV reactivation;Blood Advances;2024-08-29

2. Tuberculosis screening for patients on biologic Medications: A Single-Center experience and Society guideline Review, Monroe County, New York, 2018–2021;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

3. Clinical Mycology Today: Emerging Challenges and Opportunities;Open Forum Infectious Diseases;2024-06-27

4. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

5. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines;Blood Reviews;2024-05